Cost-effectiveness guidelines for reimbursement of pharmaceuticals: is economic evaluation ready for its enhanced status?

Health Econ. 1992 Jul;1(2):85-92. doi: 10.1002/hec.4730010202.
No abstract available

Publication types

  • Editorial

MeSH terms

  • Australia
  • Cost-Benefit Analysis
  • Drug Costs
  • Drug Evaluation / methods*
  • Guidelines as Topic
  • Insurance, Pharmaceutical Services / standards*
  • Ontario
  • Reimbursement Mechanisms